Sanofi (SNY) Share-based Compensation (2009 - 2023)
Sanofi (SNY) posted Share-based Compensation of $2.1 million for Q4 2021, down 99.96% sequentially from $5.2 billion in Q2 2021, and up 7.94% YoY from $1.9 million in Q4 2020.
Sanofi (SNY) Share-based Compensation (2009 - 2023) Analysis & Trends
Sanofi has reported Share-based Compensation for 6 years, with the latest figure at $2.1 million in Q4 2021.
- Quarterly Share-based Compensation rose 7.94% year-over-year to $2.1 million in Q4 2021, while the trailing twelve-month figure through Jun 2021 was $5.2 billion (changed N/A YoY) and the FY2025 annual result came in at $364.3 million, up 22.65% from the prior year.
- Share-based Compensation eased to $2.1 million in Q4 2021 per SNY's latest filing, from $5.2 billion in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.2 billion in Q2 2021 and troughed at $1.5 million in Q4 2019.
- A 3-year average of $1.3 billion and a median of $2.0 million in 2020 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2020 and 2021: Share-based Compensation grew 23.1% in 2020, then rose 7.94% in 2021.
- Over 3 years, Share-based Compensation stood at $1.5 million in 2019, then grew by 23.1% to $1.9 million in 2020, then advanced by 7.94% to $2.1 million in 2021.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.1 million, $5.2 billion, and $1.9 million for Q4 2021, Q2 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.81 Bn | 632.06 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 470.36 Bn | 463.79 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 375.71 Bn | 368.57 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 303.50 Bn | 295.81 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.38 Bn | 252.48 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.44 Bn | 222.45 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 181.93 Bn | 178.75 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 159.38 Bn | 147.68 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 106.17 Bn | 102.00 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.13 Bn | 47.75 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 304.49 Mn |
| Dec 31, 2023 | 304.49 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Jun 30, 2021 | 5.17 Bn |
| Jun 30, 2021 | 5.17 Bn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2020 | 1.91 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Dec 31, 2015 | 3.08 Bn |
| Dec 31, 2015 | 3.08 Bn |
| Dec 31, 2012 | 2.80 Bn |
| Dec 31, 2012 | 2.80 Bn |
| Dec 31, 2009 | 2.50 Bn |
| Dec 31, 2009 | 2.50 Bn |